CRISPR and Synthetic Biology Converge to Reprogram Extracellular Vesicles as Programmable Drug Delivery Vehicles
Background
Developing safe and effective drug delivery vehicles for targeted delivery of biomolecules to therapeutic cells has been a long-standing challenge in the field of gene therapy. Adeno-associated viruses (AAVs) and lipid nanoparticles (LNPs), which have been widely used in academia and industry, have limitations in terms of eliciting immune responses in vivo and difficulty in targeted delivery to specific tissues. In this context, extracellular vesicles (EVs), which are naturally secreted by cells and safely transport nucleic acids, proteins, and lipids between cells, are emerging as a new alternative.
EVs are derived from endogenous sources, which minimizes immunogenicity and allows them to cross biological barriers to deliver cargo directly to target cells. However, naturally occurring EVs have limitations in terms of low drug loading efficiency and difficulty in guiding them to specific target cells. To overcome these limitations and transform them into efficient drug delivery systems, it is necessary to genetically engineer the molecular composition of EVs.
Key Findings
Recent advances have revealed the complex molecular mechanisms that regulate EV biogenesis, cargo sorting, secretion, and uptake. Based on these findings, efforts have been made to combine CRISPR-Cas9 technology and synthetic biology tools to artificially control the physical properties and internal composition of EVs. This review focuses on specific engineering strategies for reprogramming EVs into artificially controllable, programmable gene delivery platforms by integrating accumulated molecular biological discoveries.
The researchers constructed synthetic biology-based genetic circuits within cells, allowing therapeutic RNA or proteins to interact organically with the membrane proteins of EVs. This genetic manipulation technique significantly improves cargo loading efficiency compared to conventional methods. In addition, the technology also enables the expression of target-specific ligand proteins on the surface of EVs, which bind only to specific target cell membranes, thereby increasing the selectivity of drug delivery.
Furthermore, a variety of analytical genetic tools fused with fluorescent and luminescent protein reporters have been introduced to track the dynamics of EVs in real-time. These tools play a crucial role in monitoring how EVs navigate between cells in vivo. In addition, the possibility of safely packaging the CRISPR-Cas9 gene editing system into EVs to selectively correct target genes has been demonstrated, paving the way for a new precision genome therapy.
Significance and Prospects
This engineering platform is expected to be a next-generation solution for delivering therapeutic substances to deep tissues in vivo, such as the blood-brain barrier (BBB), which has been a major obstacle to drug delivery. In particular, since it utilizes naturally derived cell membrane vesicles rather than artificial materials, it is expected to act as a safety mechanism by minimizing innate immune responses caused by foreign substances. However, there are still technical challenges to be overcome before it can be commercialized.
The biggest challenge is the heterogeneity of EVs, which are released from cell membranes. The size and internal cargo loading of secreted vesicles are not uniform, making it difficult to ensure consistent quality, which is a basic requirement for pharmaceuticals. In addition, the technology for large-scale production of high-purity EVs and the establishment of good manufacturing practice (GMP) standards are still in the early stages, suggesting that academia and the bioindustry need to continue to conduct joint research.
Why It Matters
This engineering technology is expected to prove its value in therapeutic scenarios that overcome the barriers of conventional cancer treatments. For example, in the treatment of patients with intractable brain tumors, conventional chemotherapeutic agents have been limited in their ability to reach the lesion due to the blood-brain barrier (BBB), which protects the brain. However, by attaching proteins that specifically target brain tumor cells to the surface of EVs derived from patient cells and loading them with CRISPR-Cas9 or small interfering RNA (siRNA) in the interior, and then administering them intravenously, the therapeutic outcome can be dramatically improved.
The EVs, which avoid the interference of the body's immune system, safely cross the BBB and penetrate into tumor cells, releasing the gene-editing material. A targeted therapy that does not harm normal brain cells but selectively targets specific genes in cancer cells will soon be available in clinical practice. Furthermore, it is expected to accelerate the commercialization of non-toxic gene therapy delivery platforms for rare diseases with clear target organs, such as genetic liver diseases and muscular dystrophy, by minimizing adverse effects in the body.
Extracellular vesicles (EVs) have emerged as promising biological nanocarriers for gene therapy due to their intrinsic ability to transport nucleic acids, proteins, and lipids between cells. Advances in EV biology have revealed complex regulatory mechanisms governing vesicle biogenesis, cargo sorting, secretion, and uptake, offering multiple opportunities for therapeutic engineering. Concurrently, modern genetic technologies, including the CRISPR-Cas9 genome editing system and synthetic biology tools, have enabled precise manipulation of EV composition and functionality. This review integrates current knowledge of EV biogenesis with emerging genetic engineering strategies to transform EVs into programmable gene delivery systems. We discuss recent advances in genetic tools for studying EV dynamics, methods for engineering EV cargo and targeting specificity, and the application of EV platforms for RNA and genome-editing therapies. Furthermore, key challenges related to vesicle heterogeneity, large-scale production, and clinical translation are examined. Finally, we highlight future perspectives on programmable EV therapeutics and their potential role in next-generation precision medicine.
This engineering technology is poised to demonstrate its value in therapeutic scenarios that overcome the barriers of conventional cancer treatments. For instance, in treating patients with intractable brain tumors, conventional chemotherapeutic agents have been severely limited by the blood-brain barrier (BBB), hindering their ability to reach the lesion. However, by attaching proteins that specifically target brain tumor cells to the surface of EVs derived from patient cells and loading them with CRISPR-Cas9 or small interfering RNA (siRNA) in the interior, followed by intravenous administration, the therapeutic outcome can be dramatically improved.
The EVs, evading the body's immune system, safely cross the BBB and penetrate into tumor cells, releasing the gene-editing material. A targeted therapy that spares normal brain cells while selectively targeting specific genes in cancer cells is on the horizon for clinical application. Furthermore, it is expected to accelerate the commercialization of non-toxic gene therapy delivery platforms for rare diseases with well-defined target organs, such as genetic liver diseases and muscular dystrophy, by minimizing adverse effects in the body.